CBMG Accelerates Cell Therapy Manufacturing with GE Healthcare’s New Start-to-Finish Solution

- January 19th, 2018

Cellular Biomedicine Group (NASDAQ:CBMG), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer, has announced its plan to configure part of its facility in Shanghai with GE Healthcare’s FlexFactory™ platform, which is expected to be designed to speed up manufacturing timelines for its cell therapy clinical trials and commercial launch. As … Continued

Cellular Biomedicine Group (NASDAQ:CBMG), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer, has announced its plan to configure part of its facility in Shanghai with GE Healthcare’s FlexFactory™ platform, which is expected to be designed to speed up manufacturing timelines for its cell therapy clinical trials and commercial launch.
As quoted in the press release:

There are more than 900 regenerative medicine trials underway globally, including trials in cell and gene therapy, a 19 percent increase since 2016.1 Despite the increased number of precision medicine trials, gaps exist in how to manufacture these precise therapies to meet demand. Scalable integrated solutions to support the transition from clinical trials to commercialization have been limited.

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply